Home＞BUSINESS
Eisai’s Midterm Strategy Focusing on Neurology, Oncology “Gradually Producing Results”: CEO Naito(Nov.2.2016)
Eisai CEO Haruo Naito |
Eisai’s strategy focusing on neurology and oncology set in its midterm business plan, dubbed “EWAY 2025” kicked off in April, “is gradually producing results,” stressed CEO Haruo Naito at an earnings briefing on October 31. “Particularly, we see steady progress in our pipeline,” he added ...
(LOG IN FOR FULL STORY)
-
Eisai CEO Sees 4 Global Brands as Drivers through FY2020
Nov.02
- Eisai’s BACE Inhibitor Enters PIII, Enrollment Begins in US Nov.01
-
Forex Moves Drag Down Eisai’s Half-Year Sales despite Bullish Global Brands
Nov.01
- 69.2% Response Rate Seen in Lenvatinib, Pembrolizumab Combination: Eisai Oct.13
- Eisai to Kick Off Global PIII for Lenvatinib as First-Line RCC Therapy Oct.03
-
- JAK Inhibitor Battle for Atopic Dermatitis Intensifying, 1st Japan Filing Might Be Near Oct.17
- Eisai Seals Latin America Pact for Belviq Oct.17
- Teva Takeda Launches Voluntary Recall for Taxotere Generics Oct.17
- Chugai’s Satralizumab Cuts Relapse Risk of Neuromyelitis Optica Spectrum Disorder Oct.16
- Ono Joins GHIT Fund as 21st Funding Partner Oct.16
- JAK Inhibitor Battle for Atopic Dermatitis Intensifying, 1st Japan Filing Might Be Near(Oct.17)
- MHLW Lifts Contraindications for Combined Statin-Fibrate Use in Renal-Impaired Patients(Oct.17)
- Eisai Seals Latin America Pact for Belviq(Oct.17)
- Teva Takeda Launches Voluntary Recall for Taxotere Generics(Oct.17)
- ADR Victim Relief Claims Fall below 1,500 in FY2017: MHLW(Oct.17)
